SAB Biotherapeutics, Inc.
SABS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $9 | $57 | $15 | $33 |
| Short-Term Investments | $12 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $6 | $8 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $2 | $1 | $9 |
| Total Curr. Assets | $24 | $59 | $22 | $50 |
| Property Plant & Equip (Net) | $20 | $25 | $28 | $31 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $20 | $25 | $29 | $31 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $44 | $84 | $51 | $81 |
| Liabilities | – | – | – | – |
| Payables | $2 | $1 | $4 | $4 |
| Short-Term Debt | $1 | $2 | $1 | $3 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $1 | $0 | $0 |
| Other Curr. Liab. | $5 | $7 | $10 | $19 |
| Total Curr. Liab. | $8 | $11 | $15 | $26 |
| LT Debt | $4 | $4 | $5 | $5 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $6 | $12 | $0 | $11 |
| Total NC Liab. | $10 | $16 | $5 | $16 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $4 | $5 | $5 | $7 |
| Total Liabilities | $18 | $27 | $20 | $43 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$124 | -$90 | -$48 | -$29 |
| AOCI | -$0 | $0 | $0 | $0 |
| Other Equity | $150 | $147 | $79 | $68 |
| Total Equity | $26 | $57 | $31 | $39 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $44 | $84 | $51 | $81 |
| Net Debt | -$4 | -$51 | -$9 | -$25 |